SynthesisFrontiers in immunology2025
Inflammatory markers from routine blood tests predict survival in multiple myeloma: a Systematic Review and meta-analysis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of daratumumab on patients with high-risk cytogenetic multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.Frontiers in immunology · 2026Pooled it
- "Prognostic Significance of Neutrophil-to-Lymphocyte, Platelet-to-Lymphocyte, and Monocyte-to-Lymphocyte Ratios in Myeloid Neoplasms: A Systematic Review".Health science reports · 2026Review
- Physical activity and cancer survival: the role of peripheral blood immune and inflammatory markers in reducing mortality-a retrospective cohort study based on NHANES 1999-2018.Translational cancer research · 2026Article
- Comparative Molecular Insights and Computational Modeling of Multiple Myeloma and Osteosarcoma.International journal of molecular sciences · 2026Review
- Prognostic value of the neutrophil-to-lymphocyte ratio in POEMS syndrome.Clinical and experimental medicine · 2026Article
- Proteasomal inhibition compromises microvascular integrity via distinct effects on non-immune endothelial cells and immune cells.Frontiers in immunology · 2026Article
- Dynamic changes in blood-derived inflammatory and bone metabolic markers for disease monitoring and prognostic assessment in multiple myeloma.American journal of translational research · 2026Article
- Association of MMP-2 and hematological parameters with breast cancer metastasis: a cross-sectional study in Central Java, Indonesia.Oncology reviews · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is an incurable hematologic malignancy marked by abnormal plasma cell proliferation. Inflammatory indices derived from routine blood tests-such as neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), red cell distribution width (RDW), RDW-to-platelet ratio (RPR), and hemoglobin-to-RDW ratio (HRR)-have shown prognostic value across cancers. This meta-analysis aimed to evaluate their prognostic significance in MM. Methods: Following PRISMA guidelines, a systematic search of PubMed, Embase, and Web of Science identified eligible studies through January 17, 2025. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Sensitivity and subgroup analyses were conducted to assess heterogeneity, and publication bias was evaluated using Egger's and Begg's tests. Results: Twenty-seven studies including 5,009 MM patients were analyzed. Elevated NLR was significantly associated with poor overall survival (OS: HR = 2.06, 95% CI: 1.72-2.47) and progression-free survival (PFS: HR = 1.70, 95% CI: 1.32-2.19), as well as advanced disease stage (OR = 2.85, 95% CI: 1.40-5.80). High RDW and low LMR were similarly linked to worse outcomes (RDW-OS: HR = 1.68; LMR-OS: HR = 0.58). PLR showed no significant association with prognosis. RPR and HRR results were inconsistent due to limited data. Conclusion: NLR, LMR, and RDW are promising prognostic biomarkers in MM, with elevated NLR and RDW and decreased LMR indicating poorer outcomes. PLR, RPR, and HRR require further investigation. These routinely accessible indices may aid in clinical risk stratification and therapeutic decision-making. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251105106, identifier CRD420251105106.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.